Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Publisher Correction: p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity.
Adriaens C, Standaert L, Barra J, Latil M, Verfaillie A, Kalev P, Boeckx B, Wijnhoven PWG, Radaelli E, Vermi W, Leucci E, Lapouge G, Beck B, van den Oord J, Nakagawa S, Hirose T, Sablina AA, Lambrechts D, Aerts S, Blanpain C, Marine JC. Adriaens C, et al. Among authors: lambrechts d. Nat Med. 2024 May;30(5):1506. doi: 10.1038/s41591-024-02842-w. Nat Med. 2024. PMID: 38332041 No abstract available.
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop.
Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M, Takeda A, Jalkanen S, Junius S, Smeets A, Nittner D, Dimmeler S, Hehlgans T, Liston A, Bosisio FM, Floris G, Laoui D, Hollmén M, Lambrechts D, Merchiers P, Marine JC, Schlenner S, Bergers G. Hua Y, et al. Among authors: lambrechts d. Cancer Cell. 2022 Dec 12;40(12):1600-1618.e10. doi: 10.1016/j.ccell.2022.11.002. Epub 2022 Nov 23. Cancer Cell. 2022. PMID: 36423635 Free PMC article.
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma.
Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, Nowosad A, Roda N, Makhzami S, Bervoets G, Maciel LF, Pulido-Vicuña CA, Pollaris L, Seurinck R, Zhao F, Flem-Karlsen K, Damsky W, Chen L, Karagianni D, Cinque S, Kint S, Vandereyken K, Rombaut B, Voet T, Vernaillen F, Annaert W, Lambrechts D, Boecxstaens V, Saeys Y, van den Oord J, Bosisio F, Karras P, Shain AH, Bosenberg M, Leucci E, Paschen A, Rambow F, Bechter O, Marine JC. Pozniak J, et al. Among authors: lambrechts d. Cell. 2024 Jan 4;187(1):166-183.e25. doi: 10.1016/j.cell.2023.11.037. Cell. 2024. PMID: 38181739 Free article.
Comparison of the single-cell and single-nucleus hepatic myeloid landscape within decompensated cirrhosis patients.
Van Melkebeke L, Verbeek J, Bihary D, Boesch M, Boeckx B, Feio-Azevedo R, Smets L, Wallays M, Claus E, Bonne L, Maleux G, Govaere O, Korf H, Lambrechts D, van der Merwe S. Van Melkebeke L, et al. Among authors: lambrechts d. Front Immunol. 2024 Feb 6;15:1346520. doi: 10.3389/fimmu.2024.1346520. eCollection 2024. Front Immunol. 2024. PMID: 38380322 Free PMC article.
PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade.
De Wispelaere W, Annibali D, Tuyaerts S, Messiaen J, Antoranz A, Shankar G, Dubroja N, Herreros-Pomares A, Baiden-Amissah REM, Orban MP, Delfini M, Berardi E, Van Brussel T, Schepers R, Philips G, Boeckx B, Baietti MF, Congedo L, HoWangYin KY, Bayon E, Van Rompuy AS, Leucci E, Tabruyn SP, Bosisio F, Mazzone M, Lambrechts D, Amant F. De Wispelaere W, et al. Among authors: lambrechts d. Clin Transl Med. 2024 May;14(5):e1655. doi: 10.1002/ctm2.1655. Clin Transl Med. 2024. PMID: 38711203 Free PMC article.
Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates.
Malengier-Devlies B, Filtjens J, Ahmadzadeh K, Boeckx B, Vandenhaute J, De Visscher A, Bernaerts E, Mitera T, Jacobs C, Vanderbeke L, Van Mol P, Van Herck Y, Hermans G, Meersseman P, Wilmer A, Gouwy M, Garg AD, Humblet-Baron S, De Smet F, Martinod K, Wauters E, Proost P, Wouters C, Leclercq G, Lambrechts D, Wauters J, Matthys P. Malengier-Devlies B, et al. Among authors: lambrechts d. Front Immunol. 2022 Oct 5;13:861251. doi: 10.3389/fimmu.2022.861251. eCollection 2022. Front Immunol. 2022. PMID: 36275702 Free PMC article.
CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy.
Franken A, Bila M, Mechels A, Kint S, Van Dessel J, Pomella V, Vanuytven S, Philips G, Bricard O, Xiong J, Boeckx B, Hatse S, Van Brussel T, Schepers R, Van Aerde C, Geurs S, Vandecaveye V, Hauben E, Vander Poorten V, Verbandt S, Vandereyken K, Qian J, Tejpar S, Voet T, Clement PM, Lambrechts D. Franken A, et al. Among authors: lambrechts d. Immunity. 2024 Mar 12;57(3):541-558.e7. doi: 10.1016/j.immuni.2024.02.007. Epub 2024 Mar 4. Immunity. 2024. PMID: 38442708
604 results